Skip to main content

Table 3 Group B (LHRH agonist) lipid profile data

From: The impact of androgen deprivation therapy on the lipid profile in patients with prostate carcinoma

  Baseline(A) 6 month(B) 12 month(C)* 24 month(D)* p value
Total cholesterol 173.1 ± 21.3 193.8 ± 32.4 171.5 ± 20.8 170.5 ± 21.1 < 0.0001
Triglycerides 109.1 ± 31.4 133.4 ± 31.3 114 ± 31.1 110.2 ± 31.6 < 0.001
HDL-cholesterol 49.2 ± 7.3 47.2 ± 7.3 47.4 ± 8.8 47.6 ± 9.4 0.69
LDL-cholesterol 103.9 ± 19.6 125.8 ± 28.9 103.1 ± 20.8 102.3 ± 22.3 < 0.0001
VLDL-cholesterol 20 ± 4.1 23.1 ± 5.1 21.9 ± 3.4 20.6 ± 4.1 0.006
  1. PSA prostate-specific antigen, HDL high-density lipoprotein, LDL low-density lipoprotein, VLDL very low-density lipoprotein
  2. *n = 38, data in mean ± SD